Skip to Main Content

San Diego biotech Halozyme announced Wednesday that it plans to buy drug development and delivery firm Antares Pharma for about $960 million.

The deal, expected to go through in the first half of this year, will pay $5.60 a share to Antares stockholders. Shares in Antares surged nearly 50% on the news within the first few hours of trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment